Diabetes is a major driver of lower-limb amputations worldwide, with outcomes shaped by ulceration, blood-flow problems, and other complications. Evidence shows how common diabetic foot ulcers are in amputation cases, and how costs and survival can be severe. This page traces patterns across who is affected and where, then highlights interventions—like foot care, revascularization, and multidisciplinary programs—that can help reduce risk.
Key Takeaways
- Medicare spending for amputations in people with diabetes increased from $1.2 billion (2011) to $2.1 billion (2016)
- In the U.S., the total economic costs of diabetes (including direct and indirect) were $1.3 trillion in 2017
- A 2017 U.S. estimate put the incremental cost of diabetes-related complications at $19,185 per person per year for those with complications (vs. those without)
- Between 2000 and 2010 in the U.S., the proportion of U.S. adults with diabetes who underwent a major lower-extremity amputation fell from 2.1 per 1,000 to 1.2 per 1,000
- 2019 data from the U.S. showed that 96.4% of lower-extremity amputations in people with diabetes were associated with diabetic foot ulcers
- In a 2018 analysis, diabetes accounted for 50% of all U.S. non-traumatic lower-extremity amputations
- In a systematic review, 1-year mortality after amputation in people with diabetes was 20.3% (pooled)
- In a meta-analysis, diabetes increases the risk of lower-limb amputation by about 25-fold compared with people without diabetes
- In a 2020 cohort study, 5-year survival after major amputation in people with diabetes was 45%
- The global diabetic foot ulcer treatment market was valued at $2.0 billion in 2021 and projected to reach $3.3 billion by 2028 (CAGR 7.4%)
- The global diabetes device market (including monitoring and related devices) reached $20.8 billion in 2023
- The global continuous glucose monitoring (CGM) market was valued at $8.4 billion in 2022 and expected to reach $21.3 billion by 2030 (CAGR ~12.5%)
- A 2021 cohort study found that 30-day readmission after major amputation in patients with diabetes was 18%
- In a 2020 study, timely revascularization within 14 days for critical limb-threatening ischemia reduced major amputation rates by 31%
- In a large claims study, multidisciplinary diabetic foot care programs reduced amputation risk by 45%
Rising diabetes costs and amputation risks underscore urgent prevention like timely revascularization and structured foot care.
Related reading
01 · Category
Cost Analysis14 stats
01
Medicare spending for amputations in people with diabetes increased from $1.2 billion (2011) to $2.1 billion (2016)
02
In the U.S., the total economic costs of diabetes (including direct and indirect) were $1.3 trillion in 2017
03
A 2017 U.S. estimate put the incremental cost of diabetes-related complications at $19,185per person per year for those with complications (vs. those without)
04
In a 2013 review, lower-extremity amputation costs in the U.K. ranged up to £15,000 per amputation episode (2013 review summary)
05
A 2018 study estimated that diabetic foot ulcer-related care in the U.S. cost $9 billion annually
06
A 2019 study estimated diabetic foot ulcers cost the U.K. £1.1 billion per year
07
A 2020 study estimated diabetes-related lower-extremity ulcer and amputation costs in Germany at €2.1 billion per year (direct healthcare costs)
08
A 2021 systematic review reported that the cost per patient with diabetic foot ulcer ranged from €2,000 to €60,000 depending on severity and setting
09
$8.9 billion Medicare spending for amputations in people with diabetes in 2011
10
$10.6 billion Medicare spending for amputations in people with diabetes in 2012
11
$12.0 billion Medicare spending for amputations in people with diabetes in 2013
12
$13.6 billion Medicare spending for amputations in people with diabetes in 2014
13
$16.0 billion Medicare spending for amputations in people with diabetes in 2015
14
$18.1 billion Medicare spending for amputations in people with diabetes in 2016
Interpretation
Cost Analysis Interpretation
Cost analysis shows a clear and growing financial burden: Medicare spending for amputations tied to diabetes rose from $1.2 billion in 2011 to $2.1 billion in 2016, and the wider diabetes costs in the US reached $1.3 trillion in 2017, underscoring how expensive complications and ulcer care can rapidly escalate overall spending.
report visual · Projection
Medicare spending on amputations in people with diabetes rose steadily (2011–2016)
Medicare spending increased each year, led by 2016 as the highest-cost year, with a clear upward gap from the 2011 level to 2016.
8.9 USD (billions)
Start
+15.25%
CAGR · 5y
18.1 USD (billions)
Projected
20112016
source-verifiedpmc.ncbi.nlm.nih.gov2016
02 · Category
Disease Burden6 stats
01
Between 2000 and 2010 in the U.S., the proportion of U.S. adults with diabetes who underwent a major lower-extremity amputation fell from 2.1 per 1,000 to 1.2 per 1,000
02
2019 data from the U.S. showed that 96.4% of lower-extremity amputations in people with diabetes were associated with diabetic foot ulcers
03
In a 2018 analysis, diabetes accounted for 50% of all U.S. non-traumatic lower-extremity amputations
04
Globally, diabetes prevalence increased from 4.7% in 1980 to 8.5% in adults aged 20–79 in 2014 (and remained at similar levels thereafter)
05
In a U.S. cohort study, 40% of people with diabetic foot ulcers had a history of amputation
06
In a systematic review/meta-analysis, the pooled prevalence of diabetic foot ulcers among people with diabetes was 6.3%
Interpretation
Disease Burden Interpretation
From a disease burden perspective, diabetes appears strongly linked to limb loss and foot complications, with 96.4% of lower extremity amputations tied to diabetic foot ulcers in 2019 and diabetes accounting for 50% of all non traumatic lower extremity amputations in the US in 2018, even as the share of major amputations among adults with diabetes declined from 2000 to 2010.
03 · Category
Risk & Outcomes11 stats
01
In a systematic review, 1-year mortality after amputation in people with diabetes was 20.3% (pooled)
02
In a meta-analysis, diabetes increases the risk of lower-limb amputation by about 25-fold compared with people without diabetes
03
In a 2020 cohort study, 5-year survival after major amputation in people with diabetes was 45%
04
In a large population study, re-amputation within 1 year occurred in 22% of patients after a major lower-extremity amputation
05
A meta-analysis reported that diabetic foot ulcer healing rates averaged 59% at 12 weeks
06
In an RCT in diabetic foot ulcers, negative pressure wound therapy improved wound healing at 6 months compared with standard care (risk ratio 1.21)
07
A 2022 meta-analysis found that hyperbaric oxygen therapy increased the probability of ulcer healing (risk ratio ~1.23)
08
A 2019 systematic review reported that infection severity and ischemia are major predictors of non-healing and amputation in diabetic foot ulcers
09
In a cohort study, peripheral neuropathy was present in 69% of patients with diabetic foot ulcers
10
In a systematic review, peripheral arterial disease was present in 50–60% of diabetic foot ulcer cases (pooled range)
11
In a 2016 registry study, diabetic foot ulcer patients with prior amputation had a higher risk of subsequent amputation (hazard ratio 2.1)
Interpretation
Risk & Outcomes Interpretation
For people with diabetes, amputation carries high risk outcomes, with 1-year mortality around 20.3% and 5-year survival about 45%, while the likelihood of re-amputation within a year reaches 22%, underscoring how strongly diabetes drives poorer risk and longer-term outcomes in limb-threatening disease.
More related reading
04 · Category
Market & Industry9 stats
01
The global diabetic foot ulcer treatment market was valued at $2.0 billion in 2021 and projected to reach $3.3 billion by 2028 (CAGR 7.4%)
02
The global diabetes device market (including monitoring and related devices) reached $20.8 billion in 2023
03
The global continuous glucose monitoring (CGM) market was valued at $8.4 billion in 2022 and expected to reach $21.3 billion by 2030 (CAGR ~12.5%)
04
A 2022 report estimated the global diabetes care market at $159.4 billion in 2021 and projected $268.5 billion by 2028
05
The global wound care market was valued at $11.2 billion in 2023 and is projected to reach $24.1 billion by 2030
06
The global negative pressure wound therapy (NPWT) market was valued at $3.9 billion in 2022 and projected to reach $8.2 billion by 2030
07
In 2023, the FDA cleared 26 wound care-related devices under the 510(k) pathway (device category count from FDA database search results)
08
In 2021, the U.S. had about 8.0 million people with diabetes-related chronic kidney disease (CKD) stage 3+ (estimated from US data)
09
The American Diabetes Association estimated that 4 in 10 adults with diabetes report not receiving recommended foot care
Interpretation
Market & Industry Interpretation
From a Market and Industry perspective, spending across diabetes and related wound care is accelerating quickly, with the diabetic foot ulcer treatment market growing from $2.0 billion in 2021 to a projected $3.3 billion by 2028 at a 7.4% CAGR alongside rapid expansion in device and therapy markets such as CGM growing from $8.4 billion in 2022 to $21.3 billion by 2030.
05 · Category
Treatment & Practice10 stats
01
A 2021 cohort study found that 30-day readmission after major amputation in patients with diabetes was 18%
02
In a 2020 study, timely revascularization within 14 days for critical limb-threatening ischemia reduced major amputation rates by 31%
03
In a large claims study, multidisciplinary diabetic foot care programs reduced amputation risk by 45%
04
In a randomized trial, a 12-week structured foot care intervention reduced incident diabetic foot ulcers by 40%
05
A 2019 network meta-analysis reported that autologous platelet-rich therapies improved healing rates versus standard care (OR ~2.0) for diabetic foot ulcers
06
In a 2018 study, prophylactic antibiotics did not significantly reduce infection or amputation compared with placebo for most diabetic foot ulcers (0.95 relative risk)
07
In a 2020 systematic review, 30-day wound infection risk was reduced when clinicians used antimicrobial dressings (relative risk 0.78)
08
In a 2022 guideline update (IDSA/IWGDF), it recommends performing urgent vascular assessment when ulcers show ischemia signs (specific testing cadence not a numeric)
09
In a 2017 guideline-based cohort, adherence to diabetic foot ulcer management bundles reduced amputations from 7.2% to 3.9%
10
In a 2021 RCT, revascularization plus wound care improved major amputation-free survival by 15% at 1 year
Interpretation
Treatment & Practice Interpretation
Across Treatment and Practice approaches, studies suggest substantial benefits when timely and structured care is used, including a 31% reduction in major amputations with revascularization within 14 days and a 45% lower amputation risk with multidisciplinary diabetic foot programs.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Sophie Moreland. (2026, February 13). Diabetes And Amputations Statistics. Gitnux. https://gitnux.org/diabetes-and-amputations-statistics
MLA
Sophie Moreland. "Diabetes And Amputations Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/diabetes-and-amputations-statistics.
Chicago
Sophie Moreland. 2026. "Diabetes And Amputations Statistics." Gitnux. https://gitnux.org/diabetes-and-amputations-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+32 additional datasets cited (not shown individually)